Cargando…

Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial

BACKGROUND: Osteoarthritis (OA) is the most common joint disorder in the USA, and knee OA has the highest prevalence. Inflammation and decrease in vascularization are key factors in the degeneration of articular cartilage and the associated pain and decrease in function. To combat this process, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ashim, Maffulli, Nicola, Rodriguez, Hugo C., Lee, Cassidy E., Levy, Howard J., El-Amin, Saadiq F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890617/
https://www.ncbi.nlm.nih.gov/pubmed/33602286
http://dx.doi.org/10.1186/s13018-021-02300-0
_version_ 1783652539644772352
author Gupta, Ashim
Maffulli, Nicola
Rodriguez, Hugo C.
Lee, Cassidy E.
Levy, Howard J.
El-Amin, Saadiq F.
author_facet Gupta, Ashim
Maffulli, Nicola
Rodriguez, Hugo C.
Lee, Cassidy E.
Levy, Howard J.
El-Amin, Saadiq F.
author_sort Gupta, Ashim
collection PubMed
description BACKGROUND: Osteoarthritis (OA) is the most common joint disorder in the USA, and knee OA has the highest prevalence. Inflammation and decrease in vascularization are key factors in the degeneration of articular cartilage and the associated pain and decrease in function. To combat this process, the use of biologics including umbilical cord-derived Wharton’s Jelly (UC-derived WJ) has grown. UC-derived WJ contains large quantities of regenerative factors, including growth factors (GFs), cytokines (CKs), hyaluronic acid (HA), and extracellular vesicles (EVs). The proposed study evaluates the safety and efficacy of intraarticular injection of UC-derived WJ for treatment of knee OA symptoms. METHODS AND ANALYSIS: This is a non-randomized, open-label, multi-center, prospective study in which the safety and efficacy of intraarticular UC-derived WJ in patients suffering from grade II/III OA will be assessed. Twelve patients with grade II/III OA who meet the inclusion and exclusion criteria will be recruited for this study which will be conducted at up to two sites within the USA. The participants will be followed for 1 s. Participants will be assessed using the Numeric Pain Rating Scale (NPRS), Knee Injury and Osteoarthritis Outcome Score (KOOS), 36-item short form survey (SF-36), Single Assessment Numeric Evaluation (SANE), physical exams, plain radiography, and Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score for improvements in pain, satisfaction, function, and cartilage regeneration. DISCUSSION: This prospective study will contribute to the limited amount of data on UC-derived WJ, particularly with regard to its safety and efficacy. The outcomes from this study will also lay the groundwork for a large placebo-controlled trial of intraarticular UC-derived WJ for symptomatic knee OA. TRIAL REGISTRATION: ClinicalTrials.gov NCT04719793. Registered on 22 January 2021
format Online
Article
Text
id pubmed-7890617
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78906172021-02-22 Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial Gupta, Ashim Maffulli, Nicola Rodriguez, Hugo C. Lee, Cassidy E. Levy, Howard J. El-Amin, Saadiq F. J Orthop Surg Res Study Protocol BACKGROUND: Osteoarthritis (OA) is the most common joint disorder in the USA, and knee OA has the highest prevalence. Inflammation and decrease in vascularization are key factors in the degeneration of articular cartilage and the associated pain and decrease in function. To combat this process, the use of biologics including umbilical cord-derived Wharton’s Jelly (UC-derived WJ) has grown. UC-derived WJ contains large quantities of regenerative factors, including growth factors (GFs), cytokines (CKs), hyaluronic acid (HA), and extracellular vesicles (EVs). The proposed study evaluates the safety and efficacy of intraarticular injection of UC-derived WJ for treatment of knee OA symptoms. METHODS AND ANALYSIS: This is a non-randomized, open-label, multi-center, prospective study in which the safety and efficacy of intraarticular UC-derived WJ in patients suffering from grade II/III OA will be assessed. Twelve patients with grade II/III OA who meet the inclusion and exclusion criteria will be recruited for this study which will be conducted at up to two sites within the USA. The participants will be followed for 1 s. Participants will be assessed using the Numeric Pain Rating Scale (NPRS), Knee Injury and Osteoarthritis Outcome Score (KOOS), 36-item short form survey (SF-36), Single Assessment Numeric Evaluation (SANE), physical exams, plain radiography, and Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score for improvements in pain, satisfaction, function, and cartilage regeneration. DISCUSSION: This prospective study will contribute to the limited amount of data on UC-derived WJ, particularly with regard to its safety and efficacy. The outcomes from this study will also lay the groundwork for a large placebo-controlled trial of intraarticular UC-derived WJ for symptomatic knee OA. TRIAL REGISTRATION: ClinicalTrials.gov NCT04719793. Registered on 22 January 2021 BioMed Central 2021-02-18 /pmc/articles/PMC7890617/ /pubmed/33602286 http://dx.doi.org/10.1186/s13018-021-02300-0 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Gupta, Ashim
Maffulli, Nicola
Rodriguez, Hugo C.
Lee, Cassidy E.
Levy, Howard J.
El-Amin, Saadiq F.
Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
title Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
title_full Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
title_fullStr Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
title_full_unstemmed Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
title_short Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
title_sort umbilical cord-derived wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890617/
https://www.ncbi.nlm.nih.gov/pubmed/33602286
http://dx.doi.org/10.1186/s13018-021-02300-0
work_keys_str_mv AT guptaashim umbilicalcordderivedwhartonsjellyfortreatmentofkneeosteoarthritisstudyprotocolforanonrandomizedopenlabelmulticentertrial
AT maffullinicola umbilicalcordderivedwhartonsjellyfortreatmentofkneeosteoarthritisstudyprotocolforanonrandomizedopenlabelmulticentertrial
AT rodriguezhugoc umbilicalcordderivedwhartonsjellyfortreatmentofkneeosteoarthritisstudyprotocolforanonrandomizedopenlabelmulticentertrial
AT leecassidye umbilicalcordderivedwhartonsjellyfortreatmentofkneeosteoarthritisstudyprotocolforanonrandomizedopenlabelmulticentertrial
AT levyhowardj umbilicalcordderivedwhartonsjellyfortreatmentofkneeosteoarthritisstudyprotocolforanonrandomizedopenlabelmulticentertrial
AT elaminsaadiqf umbilicalcordderivedwhartonsjellyfortreatmentofkneeosteoarthritisstudyprotocolforanonrandomizedopenlabelmulticentertrial